AbCellera Biologics Inc. ABCL
Updated: 18 Jun 2026
No signal published yet
We already track AbCellera Biologics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow AbCellera Biologics Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow AbCellera Biologics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 17, 2026, AbCellera announced a research collaboration with Jazz Pharmaceuticals to develop next-generation T-cell engaging antibodies for solid tumors. The agreement includes a $56 million upfront payment and potential milestone payments of up to $792 million per program. Additionally, the company reported positive interim Phase 1 clinical data for its ABCL635 program in May 2026.
What Firelda Watch includes for AbCellera Biologics Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow AbCellera Biologics Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow AbCellera Biologics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more